Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark E Jones

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Antimicrobial Agents and Chemotherapy|April 24, 2003
Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001James A Karlowsky, Deborah C Draghi, Mark E Jones, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2004
Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002Robert K Flamm, Mellany K Weaver, Clyde Thornsberry, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Reinterpretation of susceptibility data using current NCCLS breakpoint criteriaMark E Jones, James A Karlowsky, Renée Blosser-Middleton, et al.
Diagnostic Microbiology and Infectious Disease|February 23, 2002
Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999Ian A Critchley, Daniel F Sahm, Clyde Thornsberry, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2002
Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agentsMark E Jones, Renée S Blosser-Middleton, Ian A Critchley, et al.
BMC Complementary and Alternative Medicine|September 18, 2013
Perspectives of older adults on co-management of low back pain by doctors of chiropractic and family medicine physicians: a focus group studyKevin J Lyons, Stacie A Salsbury, Maria A Hondras, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2003
Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001Ian A Critchley, Renée S Blosser-Middleton, Mark E Jones, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 22, 2002
Class I integrons: prevalence and impact on antibiotic susceptibility in 278 consecutive unrelated Gram-negative blood isolatesFranz-Josef Schmitz, Pedro Martinez-Freijo, Sylvia Theis, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2002
Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalisIan A Critchley, James A Karlowsky, Deborah C Draghi, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
Longitudinal assessment of antipneumococcal susceptibility in the United StatesMark E Jones, James A Karlowsky, Renée Blosser-Middleton, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|April 24, 2003
Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001James A Karlowsky, Deborah C Draghi, Mark E Jones, et al.
Antimicrobial Agents and Chemotherapy|June 25, 2004
Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002Robert K Flamm, Mellany K Weaver, Clyde Thornsberry, et al.
Antimicrobial Agents and Chemotherapy|January 25, 2003
Reinterpretation of susceptibility data using current NCCLS breakpoint criteriaMark E Jones, James A Karlowsky, Renée Blosser-Middleton, et al.
Diagnostic Microbiology and Infectious Disease|February 23, 2002
Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999Ian A Critchley, Daniel F Sahm, Clyde Thornsberry, et al.
The Journal of Antimicrobial Chemotherapy|December 21, 2002
Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agentsMark E Jones, Renée S Blosser-Middleton, Ian A Critchley, et al.
BMC Complementary and Alternative Medicine|September 18, 2013
Perspectives of older adults on co-management of low back pain by doctors of chiropractic and family medicine physicians: a focus group studyKevin J Lyons, Stacie A Salsbury, Maria A Hondras, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2003
Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001Ian A Critchley, Renée S Blosser-Middleton, Mark E Jones, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases|February 22, 2002
Class I integrons: prevalence and impact on antibiotic susceptibility in 278 consecutive unrelated Gram-negative blood isolatesFranz-Josef Schmitz, Pedro Martinez-Freijo, Sylvia Theis, et al.
Antimicrobial Agents and Chemotherapy|January 18, 2002
Activities of faropenem, an oral beta-lactam, against recent U.S. isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalisIan A Critchley, James A Karlowsky, Deborah C Draghi, et al.
Antimicrobial Agents and Chemotherapy|July 18, 2002
Longitudinal assessment of antipneumococcal susceptibility in the United StatesMark E Jones, James A Karlowsky, Renée Blosser-Middleton, et al.
Pageof 7